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Abstract Genetic mutations have been identified as the
cause of inherited cancer risk in some colon cancer; these
mutations are estimated to account for only 5–6 % of
colorectal cancer (CRC) cases overall. Up to 25–30 % of
patients have a family history of CRC that suggests a
hereditary component, common exposures among family
members, or a combination of both. Cancers in people with
a hereditary predisposition typically occur at an earlier age
than in sporadic cases. A predisposition to CRC may
include a predisposition to other cancers, such as
endometrial cancer. We describe genetics, current diag-
nosis and management of CRC hereditary syndromes
pointing to a multidisciplinary approach to achieve the best
results in patients and family outcomes.
Keywords Hereditary colorectal cancer  Lynch
syndrome  Adenomatous polyposis  Colon cancer
Introduction
In Spain, cancer is the primary cause of death in males
(31 %) and the second major cause in women (20 %) after
cardiovascular disease. Approximately 5–10 % of cancer
has a hereditary component with high penetrance alleles. In
addition, up to 25–30 % of certain cancers such as col-
orectal cancer (CRC) have a familial component due to the
inheritance of alleles with a moderate penetrance. It is
likely that other undiscovered genes and background
genetic factors contribute to the development of familial
cancer in conjunction with non-genetic risk factors [1].
Hereditary CRC syndromes caused by known high-
penetrance genes collectively account for 5–6 % of all
cases of CRC. This group includes hereditary non poly-
posis colorectal cancer, also known as Lynch Syndrome
(LS), adenomatous (familial adenomatous polyposis [FAP]
and MUTYH-associated polyposis [MAP]) and hamar-
tomatous (Peutz-Jeghers Syndrome [PJS], Juvenile Poly-
posis Syndrome [JPS], PTEN-Hamartomatous Tumor
Syndrome [PHTS]) polyposis syndromes [2]. The altered
genes involved in cancer onset are now well known.
Almost all gene mutations known to cause a predisposition
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to CRC are inherited in an autosomal dominant fashion,
although, there is at least one example of autosomal
recessive inheritance, such as MAP.
When the family history includes two or more relatives
with CRC, the possibility of a genetic syndrome is increased
substantially. The first step in this evaluation is a detailed
review of the family history to determine the number of
relatives affected, their relationship to each other, the age at
which the CRC was diagnosed, the presence of multiple
primary CRCs, and the presence of any other cancers (e.g.,
endometrial) consistent with an inherited CRC syndrome.
Differential diagnosis is essential for management and
cancer prevention of the affected individuals, because each
syndrome has its own distinctive organ-specific manifesta-
tion and requires a different surveillance strategy. In addi-
tion, the genetic diagnosis of hereditary cancer syndromes
allows predictive genetic analysis to be performed in at risk
family members. Healthy individuals who are carriers of a
mutation are at high risk of developing certain diseases,
depending upon the syndrome. Both affected patients as well
as at risk individuals are offered screening programs perti-
nent to their situation as well as prophylactic treatment with
the aim of reducing risk and detect precursor lesions or
cancer at an early stage.
Methodology
Levels of evidence and recommendations assess the
strength of the evidence supporting the use of specific
interventions or approaches, based on the following:
Grade A (levels of evidence: Ia, Ib): requires a minimum
of a randomized clinical trial that forms part of a larger
good quality and consistent clinical trial in terms of the
specific recommendations.
Grade B (levels of evidence: IIa, IIb, III): requires the
availability of methodologically correct clinical trials that
are randomized with regard to the recommendation topic,
including trials that do not comply with the criteria A or C.
Grade C (levels of evidence: IV): requires the avail-
ability of documents and opinions from expert committees
and/or known authorities with clinical experience; indi-
cates the absence of directly applicable and high-quality
clinical studies.
Lynch syndrome (LS) (also called hereditary
nonpolyposis colorectal cancer)
Clinical and molecular diagnosis of LS
LS is an hereditary condition that increases the risk of
CRC, endometrial (EC) and other cancer types (ovarian,
upper urinary tract, gastric, small intestine, pancreas, bil-
iary tract, gliomas and sebaceous glands). It is an autoso-
mal dominant condition caused by germline mutations in
genes involved in the repair of DNA damage during DNA
replication [mismatch repair genes (MMR): MLH1, MSH2,
MSH6 y PMS2]. Also, LS is caused by deletions of
EPCAM gene, located just upstream from MSH2, through
epigenetic silencing. A mutation in one of these genes
confirms the diagnosis in the patient and in at-risk family
members.
The Amsterdam I-II clinical criteria were established to
identify families with LS. The revised Bethesda guidelines,
the most used criteria, have a better sensitivity. Computa-
tional models have been developed to calculate risk of
having an MLH1, MSH2, MSH6 gene mutation such as
MMRpredict, MMRpro, or PREMM1,2,6. When the risk of
having a MMR gene mutation calculated by computational
models is [5 %, genetic testing must be considered.
However, clinical criteria and computational models have
no optimal sensitivity and efficiency. Several studies test-
ing all CRCs reveal that up to 28 % of LS patients would
be missed with the revised Bethesda guidelines. Universal
tumor testing for DNA MMR deficiency of all CCR is cost-
effective. Immunohistochemistry (IHC) testing of tumor
tissue to detect lack of expression of MMR proteins, that
can direct germline testing, has an overall reported sensi-
tivity of 83 % and specificity of 89 %. The accuracy of
IHC depends of the experience of the laboratory perform-
ing the testing. If IHC cannot be done or the result is
ambiguous, microsatellite instability (MSI) analysis (the
Bethesda’s consensus panel defined in 1998) should be
performed. The sensitivity for MSI is estimated at 85 %,
and specificity at 90 %. If a tumor sample is not available,
germline testing is reasonable [3–6].
About 10–15 % of sporadic CRC show MSI and loss of
MLH1 protein. It can be due to somatic events such as
promoter hypermethylation or a BRAF mutation, which
increases with age. Almost no LS tumors have a BRAF
mutation [3–7].
Lynch-like syndrome defines families with MSI and/or
IHC loss of expression of the MMR gene proteins in tumor
tissue but no pathogenic germline mutation can be found
(Fig. 1).
Recommendations
Tumor testing with IHC for MMR proteins and/or MSI of
DNA should be assessed in individuals with CRC younger
than 70 years old, and in those who fulfill any of the
revised Bethesda guidelines (Grade B).
Tumors that demonstrate loss of MLH1 expression
should undergo BRAF testing or analysis for MLH1 pro-
moter hypermethylation (Grade B).
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Germline testing must be done by DNA sequencing and
large rearrangement analysis (multiplex ligation-dependent
probe amplification [MLPA]). When the gene mutation is
found, mutation-specific germline testing should be done in
the at-risk relatives (Grade A).
Management of LS
Screening of associated tumors to LS
LS shows incomplete penetrance and a variable expression.
There are some differences in the clinical phenotype of
patients with LS depending on the MMR gene mutated. The
majority of mutations described in LS are in the MLH1 and
MSH2 genes. The accumulated risk of CRC up to 70 years
varies between 34 and 47 %, for MLH1 and MSH2,
respectively. The risk of EC varies between 18 % (MLH1)
and 30 % (MSH2) [8]. The risk of extracolonic cancers as
well as multiple tumors seems to be higher in families with
an MSH2 mutation [8]. The mutations in MSH6 or PMS2
cause an attenuated phenotype (later age at diagnosis and
lower penetrance) [9–11]. The contribution of MSH6 and
PMS2 to LS is small, although recent population studies
suggest that the prevalence in families with a mutation in
these genes could be higher than that expected [12].
The precursor lesion for CRC is an adenomatous polyp
with high-grade dysplasia. The adenoma-carcinoma
sequence is accelerated (estimated at 35 months) compared
with 10–15 years in sporadic cancer [13].
Colonoscopy and removal of all polyps has demon-
strated a reduction in the incidence of CRC and the mor-
tality of individuals with LS [14].
The screening tests for gynecological cancers have a low
sensitivity/specificity [15].
All CRC< 70y and CRC>70y + revised Bethesda guidelines
IHQ and/or MSI
AbnormalNormal IHQ and 
non-MSI
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Fig. 1 Lynch syndrome:
diagnostic algorithm
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Recommendation Colonoscopy is recommended every
1–2 years starting at age 25 or 5 years younger than the
youngest case in the family (if diagnosed before age 25).
From age 40 this changes to annual screening. The upper
age limit depends upon the health of the patient (Grade B).
In carriers of MSH6 mutations colonoscopy is recom-
mended every 2–3 years starting at age 30–35 (or 10 years
before the age of the youngest case in the family). Whilst in
carriers of PMS2 mutations, screening starts at 35–40 years
of age at the same frequency (2–3 years) unless an early-
onset cancer exits in a given family (Grade B).
In women with LS, the recommended screening protocol
is a gynecological examination; transvaginal ultrasonog-
raphy with endometrial aspiration and optional CA-125
tumor marker detection is recommended starting at
30–35 years of age and performed every year (Grade C).
In families with aggregation of gastric cancer or
urothelial tumors an upper endoscopy with duo-
denoscopy every 3–5 years, starting at 30–35 years of
age and/or cytological analysis of urine and renal
ultrasonography every 1–2 years, starting at 25–30 years
of age (Grade C).
It has been suggested that families with LS have an
increased risk of breast cancer but there is insufficient
evidence to give specific screening recommendations. Nor
is there sufficient evidence for screening of other tumors
associated with LS (brain, pancreas, biliary tract, small
bowel, etc.).
Risk reducing surgery
A decision analytic model designed to compare annual
gynecologic examinations with annual screening (ultra-
sonography, endometrial biopsy, CA 125) and with hys-
terectomy with bilateral salpingo-oophorectomy at age
30 years in LS women demonstrated that surgical man-
agement led to the greatest expected life years, and when
comparing prophylactic surgery with the screening option,
one would need to perform 75 surgeries to save one
woman’s entire life. For cancer prevention, however, only
28 and 6 prophylactic surgeries would need to be per-
formed to prevent one case of ovarian and endometrial
cancer, respectively [15].
Schmeler et al. showed that in mutation-positive women
prophylactic hysterectomy with bilateral salpingo-
oophorectomy was an effective strategy for preventing
endometrial and ovarian cancer in women with the Lynch
syndrome [16].
Recommendation Female mutation carriers that no-longer
want to have children can be offered the possibility of a
hysterectomy and bilateral salpingo-oophorectomy, espe-
cially in carriers of a MSH6 mutation (Grade A).
There are no sufficient data to recommend prophylactic
colectomy in individuals at risk or mutation carriers (Grade
C).
Chemoprevention
In the CAPP2 study, 861 patients diagnosed with LS were
randomized to receive aspirin (AAS): 600 mg every 24 h
versus placebo. Those patients that received AAS for more
than 2 years had a 54 % reduction in the incidence of CRC
(hazard ratio [HR]: 0.41, confidence interval [IC] 95 %:
0.19–0.86, p = 0.02) and a reduction in the incidence of
other tumors (HR: 0.47, IC95 %: 0.21–1.06, p = 0.07). In
those patients that received AAS for less than 2 years there
was no CRC reduction benefit [17–19].
Recommendation Systematic administration of aspirin is
not recommended to prevent CCR in patients with LS
(Grade C).
Familial adenomatous polyposis (fap)
Clinical and molecular diagnosis of FAP: classical y
attenuated forms
FAP, also known as APC-Associated Polyposis, is an
inherited autosomal dominant syndrome characterized by
the development of hundreds of colorectal adenomas in the
second or third decade of life. It is the most common
gastrointestinal polyposis syndrome (1 per 10.000 sub-
jects). If patients are not treated, all will develop CRC at an
average age of 38–41 years [20]. It represents less than
1 % of all CRC cases. Extracolonic manifestations are
gastric and duodenal polyps (duodenal adenomas are found
in more than 80 % of patients, but the risk of developing a
duodenal cancer is less than 15 %) [21], desmoids tumors,
thyroidal, liver (hepatoblastoma) and brain tumors, osteo-
mas, congenital hypertrophy of retinal pigmented epithe-
lium, supernumerary teeth, epidermoid cysts and adrenal
masses.
APC is a tumor-suppressor gene located on chromo-
some 5q that plays an important role in the Wnt signaling
pathway by negatively regulating the ß-catenin oncopro-
tein. Germline mutations in APC gene are responsible for
FAP. Mutational hotspots in this gene are located in the 50
region of exon 15. Most of the germline mutations are
inherited but between 11 and 25 % of cases can be de
novo.
Attenuated FAP (AFAP) is a phenotypic variant of FAP
characterized by a mild disease course, a reduced number
of colorectal adenomas (10–99) with a right-sided distri-
bution in the colon, later age of onset a and lower CRC risk
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(up to 70 %) if patients are not treated in a timely manner
[22].
A genotype-phenotype correlation has been described.
An aggressive polyposis phenotype is associated with
mutations from codons 1250 to 1464; otherwise, AFAP is
associated with mutations located at either end of the gene
or in exon 9.
Recommendation
Patients with more than 100 colonic adenomas should be
tested for an APC gene mutation. If no mutation is detec-
ted, the MUTYH gene should be analyzed (Grade B).
When PAFA is suspected, both APC and MUTYH genes
could be analyzed. On the one hand, if autosomal dominant
inheritance is observed, the APC gene should be tested
first, whereas if recessive inheritance is observed, testing
for MUTYH should be done first (Grade B).
POLE and POLD1 genes could be evaluated for testing
if no mutation detected in APC and MUTYH and clinically
suspected (Grade B).
Massive parallel sequencing will probably change this
sequential approach.
Management of FAP and AFAP
Surgical options in FAP and AFAP
Clinical diagnosis of FAP is based on the presence of C100
polyps, and the lifetime risk to develop a cancer is 100 %
at around 50 years of age. Surgery is the most important
preventive measure in patients with FAP [23].
Surgical options in FAP patients are total abdominal
colectomy with ileorectal anastomosis (TAC/IRA) or total
protocolectomy with pouch anal anastomosis (TPC/IPAA).
If AFAP presents with fewer than 100 polyps, colec-
tomy is usually not necessary [24].
Recommendation For patients with FAP, most frequently,
after puberty has been reached or when adequate polyp
control cannot be achieved by endoscopic technique,
colectomy should be performed (except in those cases where
the size or histology recommends surgery earlier) (Grade C).
Surveillance in FAP and AFAP
Colonic surveillance
Classical FAP
The surveillance is based on colon cancer risk, median
age of diagnosis and/or surgery performed.
Recommendation In classical FAP, preoperative surveil-
lance (Grade B):
• Individuals with a family history and no familial
mutation found:
Biennial flexible sigmoidoscopy beginning from the
age of 10 to 15 years until 40 years. Every 3–5 years
until age 50 and from then on less frequently. If new
polyps are detected, a total colonoscopy should be
done; both the follow up and treatment will be the
same as a regular patient [25].
• Individuals with a positive genetic test:
Biennial flexible sigmoidoscopy beginning from the
age of 10 to 15 years. Once adenomatous polyps have
been identified, colonoscopy shouldbeperformedonan
annual basis until the patient undergoes surgery [25].
Surveillance after colectomy (Grade B):
• In TAC/IRA patients, proctoscopy every 6–12 months
is recommended [25].
• In TPC/IPAA patients, ileoscopy is recommended
every 1–3 years, depending on the detection of adeno-
matous transformation [25].
AFAP
Average age of cancer development is 55 years; diag-
nosis before 20 years is extremely unusual.
Recommendation Biennial colonoscopy should be per-
formed beginning from 18 to 20 years (Grade B).
Extracolonic surveillance
• Upper gastrointestinal tract.
Duodenal polyps are found frequently (around
50–90 %).
Duodenoscopic findings are assessed using the Spigel-
man classification (which describes 5 stages assessing the
polyp number, size, histology and type of dysplasia).
Duodenal cancer risk is 5 %, increasing to 36 % in
patients with Spigelman stage III–IV [25].
Recommendation Recommendations are different depend-
ing on the stage (duodenoscopic from 5 years in stage 0/I to
propose surgery in stage IV). Upper endoscopy and Vater´s
ampoule endoscopy should begin between 25 and 30 years.
• Desmoids tumors:
Approximately 10–15 % of mutation carriers will
develop a desmoids tumor, usually intra-abdominal. Risk
factors are abdominal surgery, family history and mutation
in 1444 codon [25].
Recommendation Computed tomography (CT) and mag-
netic resonance imaging (MRI) are useful when a desmoids
tumor is suspected.
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Non-steroidal anti-inflammatory drugs (NSAIDs) vs
sulinac with tamoxifen are recommended (Grade B). After
progression chemotherapy should be used: dacarbazine,
methotrexate, vinblastine or radiotherapy. Surgery is con-
troversial and should be reserved for abdominal compli-
cations (bowel obstruction, intestinal ischemia) (Grade B).
• Thyroid:
Patients with classical FAP have a lifetime thyroid
cancer risk of 2–6 % and female predominance (95 %).
Peak of incidence is in the third decade of life [25].
Recommendation Annual thyroid physical examination
and ultrasound are recommended beginning from the age
of 15 years (Grade C).
• Hepatoblastoma
The risk for hepatoblastoma in FAP is 750 to 7500 times
higher than in the general population, although the absolute
risk is estimated at less than 2 %. The majority of hepa-
toblastomas occur prior to the age of 3 years [26].
Recommendation Screening for hepatoblastoma in FAP
using frequent (every 2–3 months) abdominal ultrasound
examinations and measurement of serum alpha-fetoprotein
concentrations may be considered from infancy to the age
of 5 years. However, the optimal interval for hepatoblas-
toma screening in FAP is not known (Grade C).
Chemoprevention in FAP and AFAP
Cyclooxygenase-2 (COX-2) has been shown to be over-
expressed in colorectal adenomatous polyps and cancers.
NSAIDs have been shown to reduce the incidence and
recurrence of colorectal adenomatous polyps [25].
Recommendation Sulindac and celecoxib have an addi-
tional role to surgery; nonetheless, they should never
replace surgery and should not be recommended in those
patients with any cardiovascular disease (Grade C). It is
also important to continue an endoscopic surveillance in
patients with residual polyps.
Mutyh-associated polyposis (map)
Clinical and molecular diagnosis of MAP
MAP is caused by biallelic mutations in MUTYH that is
characterized by an increased lifetime risk of CRC (43 % to
almost 100 %). MAP is suspected in an individual who has:
colonic adenoma count between one and ten before the age
of 40; colonic adenoma and/or hyperplastic polyp count
between ten and a few hundred; colonic polyposis (i.e.,
[100 colonic polyps) in the absence of a germline APC
mutation; CRC with the somatic KRAS mutation c.34G[T
in codon 12; and, family history of CRC (with or without
polyps) consistent with autosomal recessive inheritance [27].
The diagnosis is determined in individuals with char-
acteristic clinical findings and biallelic MUTYH mutations
[28]. Two common mutations, c.536A[G (p.Tyr179Cys)
in exon 7 and c.1187G[A(p.Gly396Asp) in exon 13,
account for up to 70 % of persons with MAP [29].
Recommendation
Offer molecular genetic testing for the familial mutations
to all siblings of an individual with genetically confirmed
MAP to reduce morbidity and mortality through early
diagnosis and treatment (Grade A).
Management of MAP
Typically associated with ten to a few hundred colonic
adenomatous polyps that are evident at a mean age of about
50 years, colonic cancer develops in some individuals with
biallelic MUTYH mutations in the absence of polyposis
[30]. Duodenal adenomas are found in 17–25 % of indi-
viduals with MAP; the lifetime risk of duodenal cancer is
about 4 %. Also there is a modestly increased risk for other
malignancies of the ovary, bladder, and skin, and some
evidence for an increased risk for breast and EC [31]. More
recently, thyroid abnormalities (multinodular goiter, single
nodules and papillary thyroid cancer) have been reported in
some studies. Some affected individuals develop sebaceous
gland tumors.
Available data suggest that heterozygous relatives of
patients with MAP have a two- or at most threefold
increase in their risk for colorectal cancer at an age similar
to that in the general population [32].
Recommendation
Suspicious polyps identified on colonoscopy should be
removed until polypectomy alone cannot manage the large
size and density of the polyps, at which point either
subtotal colectomy or proctocolectomy is performed
(Grade A). Duodenal polyps showing dysplasia or villous
changes should be excised during endoscopy (Grade A).
Abnormal findings on thyroid ultrasound examination
should be evaluated by a thyroid specialist to determine
what combination of monitoring, surgery, and/or fine
needle aspiration (FNA) is appropriate (Grade C).
Surveillance for individuals with biallelic MUTYH
germline mutations should be performed by pancolonoscopy
beginning at age 18–20 years; upper endoscopy with side
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viewing duodenoscopy beginning at age 25–30 years; fol-
low-up depending on disease severity (Grade A).
There are no specific screening recommendations for
individuals heterozygous for a MUTYH mutation. They are
expected to benefit from population screening measures or
could be offered average moderate-risk colorectal screen-
ing based on family history (Grade C).
Peutz-jeghers syndrome (pjs)
Clinical diagnosis and genetic testing
PJS is an autosomal dominant hereditary condition char-
acterized by the association of hamartomatous gastroin-
testinal polyposis, typical mucocutaneous pigmentation
and cancer predisposition. Peutz-Jeghers polyps are more
common in the small intestine but can also occur in the
stomach, large bowel and extra-intestinal sites. Hyper-
pigmentation is typically present in childhood around the
mouth, eyes, nostrils, oral mucosa and fingers and may fade
in puberty and adulthood. Individuals with PJS are at
increased risk for a wide variety of cancers: epithelial
malignancies (colorectal, gastric, pancreatic, breast and
ovarian), adenoma malignum of the cervix (females) and
some benign male and female genital tumors.
Clinical diagnosis of PJS is based on any of the fol-
lowing criteria [33]:
• Two or more histologically confirmed PJS-type hamar-
tomatous polyps.
• Any number of PJS-type polyps detected in one
individual who has a family history of PJS in a close
relative.
• Characteristic mucocutaneous pigmentation in an indi-
vidual who has a family history of PJS in a close
relative.
• Any number of PJS-type polyps in an individual who
also has characteristic mucocutaneous pigmentation.
Genetic testing of STK11/LKB1 gene can find patho-
genic variants in 80–94 % of the affected individuals.
Approximately 45 % of affected individuals have no
family history.
Management of PJS
Upper and lower endoscopies may allow early detection of
colorectal and upper gastrointestinal cancers. Colorectal
cancer risk has been reported from age 27 to 71 with 39 %
lifetime risk estimates. Lower estimates have been descri-
bed for upper gastrointestinal cancer [34].
The other indication for endoscopic surveillance is early
detection and prevention of polyp related complications.
Cumulative breast cancer risk estimates range from 31 to
54 % at age 60, with a mean age at diagnosis of 37 [34, 35].
Recommendation
Endoscopic surveillance from age 8 including upper
endoscopy and video capsule endoscopy or magnetic res-
onance enterography and colonoscopy may allow early
diagnosis of polyposis and appropriate treatment. If a sig-
nificant polyposis is found, endoscopy should be repeated
every three years: if not then from age 18 and every three
years. At age 50 the endoscopy should be performed every
1–2 years (Grade C)
Annual breast MRI examinations in females aged 25–30
and mammograms from age 50 are recommended. Routine
pap smears from age 25 every 2–3 years using liquid based
cytology are also recommended (Grade C).
Regular testicular examinations and testicular ultra-
sound in the case of abnormal findings is recommended
from the pediatric age (Grade C).
Juvenile polyposis syndrome (jps)
Clinical diagnosis and genetic testing
JPS is characterized by predisposition to specific hamar-
tomatous polyps (‘‘juvenile polyps’’) in the stomach, small
intestine, colon and rectum. Most juvenile polyps are
benign and may cause anemia and bleeding. Malignant
transformation of the gastrointestinal tract is mainly due to
colon cancer but also gastric, upper GI tract and pancreatic
cancer have been reported.
Any of the three following criteria is clinical diagnostic
of Juvenile Polyposis Syndrome:
– 5 or more juvenile polyps of the colorectum.
– Multiple juvenile polyps throughout the GI tract.
– Presence of any number of juvenile polyps and family
history of JPS.
Approximately 20 % of individuals have pathogenic
variants in BMPR1A and 20 % in SMAD4. Most individ-
uals with SMAD4 variants may present with a combined
syndrome: JPS and hereditary hemorrhagic telangiectasia.
In 25 % of probands with JPS there is no family history
and they may harbor de novo mutations [36].
Management of JPS
Upper and lower endoscopies may allow early detection of
CRC and upper gastrointestinal cancers. In large kindreds,
the CRC risk estimate was 38 % and upper gastrointestinal
cancer 20 %. The youngest CRC diagnosis was at age 17
968 Clin Transl Oncol (2015) 17:962–971
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and the youngest upper gastrointestinal cancer was at age
20 [37].
Recommendation
Colonoscopy and upper GI endoscopy beginning at age 15
and at least every 3 years and appropriate polypectomy or
surgery if needed is recommended (Grade C).
Serrated polyposis syndrome (sps)
Clinical and genetic diagnostics
SPS is characterized by the presence of multiple serrated
polyps and/or of a large size in the colon that predisposes
an increased risk to develop CRC [38].
A clear genetic etiology is not confirmed. In presence of
concurrent adenomas the study of MUTYH mutations may
be done [39].
The management is empirical and includes the resection
of the polyps, endoscopic surveillance and genetic coun-
seling. A colectomy with IRA is recommended before
discovering a CRC.
Recommendation
Complete resection and endoscopic surveillance every 5
years from 35 to 40 years of age (or 10 years before the
youngest case in the family).
With regard to the risk of CRC in first-degree relatives,
surveillance colonoscopy is recommended every 5 years
from 35 to 40 years of age (or 10 years before the youngest
case in the family), modifying the protocol if polyps are
found (Grade B).
Hamartomatosis syndrome associated with pten
(phts)/cowden syndrome
Clinical and genetic diagnostics of PHTS
PHTS is characterized by muco-cutaneous lesions of a
papillomatosis form on the face and mouth with a typical
cobbled appearance, acral keratosis, macrocephaly, the
development of a dysplastic gangliocytoma of the cere-
bellum, thyroid and breast lesions, gastrointestinal polyps
or uterine leiomyomas [40]. The risk of developing breast
cancer is from 25 to 50 %, thyroid cancer from 3 to 10 %
and EC from 5 to 10 %. Up to 92 % of the cases of
Cowden have polyps and the prevalence of CRC is from 9
to 18 % [41].
It is inherited in an autosomal dominant manner and
forms part of the clinical spectrum of diseases associated
with a germline mutation in PTEN [42].
Management of PHTS
There is no curative treatment for these syndromes,
although muco-cutaneous lesions should be treated by
surgery (curettage or cryosurgery), as they are not usually
resolved with topical treatment. The facial tricholemmo-
mas respond to the usual laser treatment.
There are no data that support the efficacy of prophy-
lactic surgery with regard to the reduction in the risk of
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Fig. 2 Adenomatous polyposis:
diagnostic algorithm. Grade of
recommendation: B
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Recommendation
The recommendations include breast, thyroid and skin
surveillance, basal colonoscopy basal at 50 years of age
and screening for endometrial cancer (Grade B).
Other genes involved in genetic predisposition
to crc (polymerase proofreading-associated
syndrome)
Germ-line mutations in the exonuclease (proofreading)
domain of DNA polymerase POLE and POLD1 have been
recently associated with a dominantly inherited syndrome
that confers increased risk to polyposis and CRC.
These genes have been studied by a Spanish group in
529 kindred (441 with familial nonpolyposis CRC and 88
with polyposis) using massively parallel sequencing iden-
tifying 7 genetic variants (the POLE p.L424V mutation
was associated with polyposis, CRC and oligoden-
droglioma) and 6 POLD1 variants with strong evidence for
pathogenicity were identified in nonpolyposis CRC fami-
lies [43].
POLD1 mutations have been associated with EC and
breast tumors, as well.
Therefore, the genetic testing of these two genes should
be recommended if a clinical phenotype is suspected
(Fig. 2).
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